A once-yearly PrEP? Gilead's lenacapavir shows promise as company plots phase 3

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart at only once a year.